Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Prevalence of Neuromyelitis Optica Spectrum Disorder in 27 Major Markets 2019-2029: Cause, Risk Factors, Prevention, Diagnosis & Prognosis - ResearchAndMarkets.com

January 16, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Jan 16, 2020--

The “Prevalence of Neuromyelitis Optica Spectrum Disorder in 27 Major Markets 2019-2029” report has been added to ResearchAndMarkets.com’s offering.

Neuromyelitis Optica, also referred to as Devic’s disease is a chronic condition of the brain and spinal cord, characterised by inflammation of the optic nerve (nerve neuritis), and spinal cord (myelitis). The progression of disease initiates whereby the body’s immune system mistakenly attacks healthy cells and neuronal sheath, myelin in the spinal cord and eyes.

This report provides the current prevalent population for Neuromyelitis Optica (NMO) across 27 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Ireland, Japan, China, South Korea, India, Belgium, Netherlands, Norway, Sweden, Finland, Austria, Switzerland, Poland, Russia, Brazil, Mexico, Argentina, Australia) split by gender and 5-year age cohort.

In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team, Neuromyelitis Optica patients grouped by diagnostic criteria, features associated with Neuromyelitis Optica, and comorbidities quantified and presented parallel to over general prevalence figures. Inclusive of the report are the sub-populations within the main disease and are included at country level across the 10-year forecast period.

Main symptoms associated with Neuromyelitis Optica include:

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All sources used to generate the data and analysis have been identified in the report.

Reason to buy

Key Topics Covered:

For more information about this report visit https://www.researchandmarkets.com/r/kga93u

View source version on businesswire.com:https://www.businesswire.com/news/home/20200116005461/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 01/16/2020 08:32 AM/DISC: 01/16/2020 08:32 AM